Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Influence of Synthetic Oestrogens on Advanced Malignant Disease.

Haddow A, Watkinson JM, Paterson E, Koller PC.

Br Med J. 1944 Sep 23;2(4368):393-8. No abstract available.

2.

Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix.

Zhang Y, Zhao H, Asztalos S, Chisamore M, Sitabkhan Y, Tonetti DA.

Mol Cancer Res. 2009 Apr;7(4):498-510. doi: 10.1158/1541-7786.MCR-08-0415.

3.

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.

Kang MH, Reynolds CP.

Clin Cancer Res. 2009 Feb 15;15(4):1126-32. doi: 10.1158/1078-0432.CCR-08-0144. Review.

4.

NF-kappaB suppression provokes the sensitization of hormone-resistant breast cancer cells to estrogen apoptosis.

Lobanova YS, Scherbakov AM, Shatskaya VA, Evteev VA, Krasil'nikov MA.

Mol Cell Biochem. 2009 Apr;324(1-2):65-71. doi: 10.1007/s11010-008-9985-0. Epub 2008 Dec 20.

PMID:
19096761
5.

Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.

Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC.

Breast Cancer Res. 2008;10(6):R104. doi: 10.1186/bcr2208. Epub 2008 Dec 5.

6.

Regulation of estrogenic effects by beclin 1 in breast cancer cells.

John S, Nayvelt I, Hsu HC, Yang P, Liu W, Das GM, Thomas T, Thomas TJ.

Cancer Res. 2008 Oct 1;68(19):7855-63. doi: 10.1158/0008-5472.CAN-07-5875.

7.

Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer.

Iwase H.

Breast Cancer. 2008;15(4):278-90. doi: 10.1007/s12282-008-0071-y. Epub 2008 Sep 23. Review.

PMID:
18810576
8.

Drug discovery approaches targeting the PI3K/Akt pathway in cancer.

Garcia-Echeverria C, Sellers WR.

Oncogene. 2008 Sep 18;27(41):5511-26. doi: 10.1038/onc.2008.246. Review.

PMID:
18794885
9.

Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.

Zeitlin BD, Zeitlin IJ, Nör JE.

J Clin Oncol. 2008 Sep 1;26(25):4180-8. doi: 10.1200/JCO.2007.15.7693. Review.

10.

Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.

Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K, Eguchi H.

Adv Exp Med Biol. 2008;630:19-34. Review.

11.

Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer.

Swaby RF, Jordan VC.

Clin Breast Cancer. 2008 Apr;8(2):124-33. doi: 10.3816/CBC.2008.n.012. Review.

PMID:
18621608
12.

The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?

Jordan VC.

J Clin Oncol. 2008 Jun 20;26(18):3073-82. doi: 10.1200/JCO.2008.17.5190. Epub 2008 Jun 2.

PMID:
18519949
13.

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

Arpino G, Wiechmann L, Osborne CK, Schiff R.

Endocr Rev. 2008 Apr;29(2):217-33. doi: 10.1210/er.2006-0045. Epub 2008 Jan 23. Review.

14.

Therapeutic targeting of apoptosis pathways in cancer.

Ziegler DS, Kung AL.

Curr Opin Oncol. 2008 Jan;20(1):97-103. Review.

PMID:
18043263
15.

Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts.

Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, Takaoka K, Martin TJ, Chambon P, Kato S.

Cell. 2007 Sep 7;130(5):811-23.

16.

Membrane-associated estrogen receptor signaling pathways in human cancers.

Pietras RJ, Márquez-Garbán DC.

Clin Cancer Res. 2007 Aug 15;13(16):4672-6. Review. No abstract available.

17.

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.

O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.

J Clin Oncol. 2007 Mar 20;25(9):1114-20. Epub 2007 Feb 12. Erratum in: J Clin Oncol. 2008 Feb 10;26(5):820.

PMID:
17296974
18.

Osteoclasts: what do they do and how do they do it?

Teitelbaum SL.

Am J Pathol. 2007 Feb;170(2):427-35.

19.

JNK pathway regulates estradiol-induced apoptosis in hormone-dependent human breast cancer cells.

Altiok N, Koyuturk M, Altiok S.

Breast Cancer Res Treat. 2007 Nov;105(3):247-54. Epub 2006 Dec 23.

PMID:
17187235
20.

Current insights into the regulation of programmed cell death by NF-kappaB.

Dutta J, Fan Y, Gupta N, Fan G, Gélinas C.

Oncogene. 2006 Oct 30;25(51):6800-16. Review.

PMID:
17072329

Supplemental Content

Support Center